» Articles » PMID: 24062306

The N-terminal Flanking Region of the A1 Domain Regulates the Force-dependent Binding of Von Willebrand Factor to Platelet Glycoprotein Ibα

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2013 Sep 25
PMID 24062306
Citations 62
Authors
Affiliations
Soon will be listed here.
Abstract

Binding of platelet glycoprotein Ibα (GPIbα) to von Willebrand factor (VWF) initiates platelet adhesion to disrupted vascular surface under arterial blood flow. Flow exerts forces on the platelet that are transmitted to VWF-GPIbα bonds, which regulate their dissociation. Mutations in VWF and/or GPIbα may alter the mechanical regulation of platelet adhesion to cause hemostatic defects as found in patients with von Willebrand disease (VWD). Using a biomembrane force probe, we observed biphasic force-decelerated (catch) and force-accelerated (slip) dissociation of GPIbα from VWF. The VWF A1 domain that contains the N-terminal flanking sequence Gln(1238)-Glu(1260) (1238-A1) formed triphasic slip-catch-slip bonds with GPIbα. By comparison, using a short form of A1 that deletes this sequence (1261-A1) abolished the catch bond, destabilizing its binding to GPIbα at high forces. Importantly, shear-dependent platelet rolling velocities on these VWF ligands in a flow chamber system mirrored the force-dependent single-bond lifetimes. Adding the Gln(1238)-Glu(1260) peptide, which interacted with GPIbα and 1261-A1 but not 1238-A1, to whole blood decreased platelet attachment under shear stress. Soluble Gln(1238)-Glu(1260) reduced the lifetimes of GPIbα bonds with VWF and 1238-A1 but rescued the catch bond of GPIbα with 1261-A1. A type 2B VWD 1238-A1 mutation eliminated the catch bond by prolonging lifetimes at low forces, a type 2M VWD 1238-A1 mutation shifted the respective slip-catch and catch-slip transition points to higher forces, whereas a platelet type VWD GPIbα mutation enhanced the bond lifetime in the entire force regime. These data reveal the structural determinants of VWF activation by hemodynamic force of the circulation.

Citing Articles

What is the Reason That the Pharmacological Future of Chemotherapeutics in the Treatment of Lung Cancer Could Be Most Closely Related to Nanostructures? Platinum Drugs in Therapy of Non-Small and Small Cell Lung Cancer and Their Unexpected, Possible....

Szupryczynski K, Czelen P, Jelinski T, Szefler B Int J Nanomedicine. 2024; 19:9503-9547.

PMID: 39296940 PMC: 11410046. DOI: 10.2147/IJN.S469217.


Von Willebrand factor and hematogenous cancer metastasis under flow.

Xu W, Tan X, Li M, Xu H, Villegas J, Fu H Front Cell Dev Biol. 2024; 12:1435718.

PMID: 39282473 PMC: 11401050. DOI: 10.3389/fcell.2024.1435718.


Protein disulfide isomerase cleaves allosteric disulfides in histidine-rich glycoprotein to regulate thrombosis.

Lv K, Chen S, Xu X, Chiu J, Wang H, Han Y Nat Commun. 2024; 15(1):3129.

PMID: 38605050 PMC: 11009332. DOI: 10.1038/s41467-024-47493-0.


Extracellular Matrix Cues Regulate Mechanosensing and Mechanotransduction of Cancer Cells.

Mierke C Cells. 2024; 13(1).

PMID: 38201302 PMC: 10777970. DOI: 10.3390/cells13010096.


Molecular mechanisms of catch bonds and their implications for platelet hemostasis.

Belyaev A, Fedotova I Biophys Rev. 2023; 15(5):1233-1256.

PMID: 37974999 PMC: 10643804. DOI: 10.1007/s12551-023-01144-8.


References
1.
Doggett T, Girdhar G, Lawshe A, Miller J, Laurenzi I, Diamond S . Alterations in the intrinsic properties of the GPIbalpha-VWF tether bond define the kinetics of the platelet-type von Willebrand disease mutation, Gly233Val. Blood. 2003; 102(1):152-60. DOI: 10.1182/blood-2003-01-0072. View

2.
Yago T, Lou J, Wu T, Yang J, Miner J, Coburn L . Platelet glycoprotein Ibalpha forms catch bonds with human WT vWF but not with type 2B von Willebrand disease vWF. J Clin Invest. 2008; 118(9):3195-207. PMC: 2518822. DOI: 10.1172/JCI35754. View

3.
Marshall B, Long M, Piper J, Yago T, McEver R, Zhu C . Direct observation of catch bonds involving cell-adhesion molecules. Nature. 2003; 423(6936):190-3. DOI: 10.1038/nature01605. View

4.
Sarangapani K, Yago T, Klopocki A, Lawrence M, Fieger C, Rosen S . Low force decelerates L-selectin dissociation from P-selectin glycoprotein ligand-1 and endoglycan. J Biol Chem. 2003; 279(3):2291-8. DOI: 10.1074/jbc.M310396200. View

5.
Huizinga E, Tsuji S, Romijn R, Schiphorst M, de Groot P, Sixma J . Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain. Science. 2002; 297(5584):1176-9. DOI: 10.1126/science.107355. View